IMV Inc., a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma. It is also developing DPX-COVID-19, a second-generation vaccine against severe acute respiratory syndrome coronavirus 2; and DPX-RSV, a vaccine candidate, which has completed Phase I clinical trials for the treatment of respiratory syncytial virus strain A, as well as DPX-SurMAGE for the treatment of bladder cancer and DPX-BRAF to treat melanoma patients. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
IPO Year:
Exchange: NASDAQ
Website: imv-inc.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/22/2021 | $4.00 | Overweight | Cantor Fitzgerald |
| 7/23/2021 | $14.00 | Overweight | Wells Fargo |
Cantor Fitzgerald initiated coverage of IMV with a rating of Overweight and set a new price target of $4.00
Wells Fargo resumed coverage of IMV with a rating of Overweight and set a new price target of $14.00
15-12G - IMV Inc. (0001734768) (Filer)
F-10POS - IMV Inc. (0001734768) (Filer)
F-10POS - IMV Inc. (0001734768) (Filer)
F-10POS - IMV Inc. (0001734768) (Filer)
S-8 POS - IMV Inc. (0001734768) (Filer)
S-8 POS - IMV Inc. (0001734768) (Filer)
S-8 POS - IMV Inc. (0001734768) (Filer)
S-8 POS - IMV Inc. (0001734768) (Filer)
S-8 POS - IMV Inc. (0001734768) (Filer)
6-K - IMV Inc. (0001734768) (Filer)
SC 13G - IMV Inc. (0001734768) (Subject)
SC 13G/A - IMV Inc. (0001734768) (Subject)
SC 13G/A - IMV Inc. (0001734768) (Subject)
Reorganization enhances organizational focus on strategic priorities Clinical update on DLBCL patients in Phase 2B VITALIZE trial to be provided in September Appointment of Dr. Saman Maleki to Board of Directors Brittany Davison promoted to Chief Accounting Officer IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced a strategic reorganization together with the appointment of Dr. Saman Maleki to the Company's Board of Directors and promotion of Brittany Davison to Chief Accounting Officer. "We have m
IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the voting results from its annual and special meeting of shareholders held on June 29, 2022 (the "Meeting"). Based on the votes received, all resolutions were accepted, including the election of directors, for whom details of the votes are as follows: Name of nominee Votes FOR % of votes FOR Votes Withheld % of votes Withheld Michael Bailey 27,525,895 99.11% 246,171 0.89% Brittany Davison 27,582,627 99.32% 189,439 0.68%
IMV Inc. (NASDAQ:IMV, TSX:IMV), ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid tumors and blood cancers, announced today that its Board of Directors has appointed Andrew Hall to the role of Chief Executive Office and Director of the Board, effective January 1, 2022. "On behalf of the Board and the Company, I congratulate Andrew on his appointment to the Chief Executive Officer role. Over the last 5 months, Andrew has demonstrated strong leadership and refocused the Company to capitalize on its strengths in immuno-oncology, as well as a strategy designed to fully realize IMV's clear poten
Frederic Ors to Step Down as CEO CBO Andrew Hall Appointed Interim CEO Board Initiating Search for Permanent Successor IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that Frederic Ors has stepped down as Chief Executive Officer (CEO), effective immediately. The IMV Board has appointed Andrew Hall, the Company's Chief Business Officer, as Interim CEO. The Company's Board is commencing a comprehensive search process to identify a permanent CEO. "On behalf of the Board and everyone at IMV, I want to thank Fred for his valuable contributions and years of service to IMV,"
IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company, today announced the voting results from its annual and special meeting of shareholders held on June 18, 2021 (the "Meeting"). Based on the votes received, all resolutions were accepted including the election of directors, for whom details of the votes are as follows: Name of nominee Votes cast FOR % of votes cast FOR Votes Withheld % of votes Withheld Andrew Sheldon 24,451,349 61.96 15,009,890 38.04 Michael Bailey 29,789,424 75.49 9,671,815 24.51 Julia P. Gregory 24,554,616 62.22 14,906,623 37.78 Michael Kalos 30,132,
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced the appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer, effective as of June 14, 2021. Dr. Graff brings over 20 years of experience in preclinical and clinical research and translational analysis for novel immune-activating therapeutics in oncology. “We are thrilled to add a seasoned scientist and industry leader like Jeremy to our team to help oversee this critical period of clinical development for maveropepimut-S,” said Fred Ors, Chief Executive Office
IMV continues to add industry expertise with appointment of Dr. Michael Kalos, an internationally recognized expert in T cell therapy and immunotherapy James Hall to retire at the AGM after 11 years as a board member IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced the appointment of Dr. Michael Kalos, to its board of directors effective today. Dr. Kalos is an internationally recognized expert in T cell therapy and immunotherapy and brings over 25 years of experience from both industry and academia. His previous career highlights include serving as Vice President of Immuno-oncol
IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the "Initial Order") granting the Company and its subsidiaries prote
- First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with Committed Backlog of $218 Million, Including $187 Million in HRZN Commitments - - Declares Regular Monthly Distributions Totaling $0.33 per Share - FARMINGTON, Conn., May 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and
IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that the Nova Scotia Supreme Court (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries protection under the Companies' Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the "CCAA"). The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code. After a careful review of available
IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that on March 29, 2023, IMV Inc. (the "Company") received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that, based upon the closing bid price of the Company's common shares for the 30 consecutive business day period between February 14, 2023, through March 28, 2023, the Company did not meet the minimum bid price of US$1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listi
IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors ("Board") of the Company, effective immediately. Dr. Tilley, Managing Partner at CTI Life Sciences Fund ("CTI LSF"), was originally appointed to the IMV Board in 2016 as a representative from CTI LSF following their initial investment in IMV. Dr. Tilley's resignation arose due to policy changes surrounding board positions at CTI LSF and she will remain IMV's point of contact at CTI LSF.
Advanced lead candidate, MVP-S, in two global Phase 2B clinical trials and enhanced the scientific differentiation of the DPX platform Observed multiple complete clinical responses in relapsed/refractory DLBCL and expect to complete enrollment of stage one in the VITALIZE study in Q2 2023 Accelerated enrollment of stage one in the AVALON study in ovarian cancer expected in Q3 2023 Strengthened financial position with $9M financing Retained Stonegate Healthcare Partners, L.L.C. for the exploration of strategic alternatives IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform
IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company's 2022 fourth quarter and fiscal year-end financial and operational results. Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information. Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations. The webcast will be
Early analysis reveals clinically meaningful activity in refractory DLBCL patients Multiple confirmed complete responses observed in heavily pre-treated patients No adverse safety and tolerability signal reported, consistent with previous clinical trials IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S ("MVP-S"), in combination with pembrolizumab in patients with relapsed, refractory Diffuse
Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023 Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023 Recently strengthened financial position with the completion of a $9M financing Appoints Shabnam Kazmi to its Board of Directors following the retirement of Julia P. Gregory IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today outlined its planned 2023 milestones to advance the clinical d
IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company's immune-educating platform, DPX®, to potentially treat solid and hematologic cancers, announced today the closing of its previously announced registered direct offering (the "Offering") for the sale of an aggregate of 3,448,276 common shares (or common share equivalents) (each, a "Share" and, collectively, the "Shares") and warrants to purchase up to an aggregate of 3,448,276 common shares (each, a "Warrant" and, collectively, the "Warrants") at a purchase price of US$2.61 per common share (or common share equivalent) and accompanying W
- First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with Committed Backlog of $218 Million, Including $187 Million in HRZN Commitments - - Declares Regular Monthly Distributions Totaling $0.33 per Share - FARMINGTON, Conn., May 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and
IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company's 2022 fourth quarter and fiscal year-end financial and operational results. Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information. Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations. The webcast will be
IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the third quarter ended September 30, 2022. "IMV worked diligently to deliver on our clinical goals in the third quarter. We restructured the business to facilitate the achievement of these objectives and remain on track to present meaningful clinical data early next year," said Andrew Hall, Chief Executive Officer of IMV. "We expect 2023 to be a potentially transformative year for IMV, w
IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, November 11, 2022, at 8:00 a.m. ET to discuss the company's 2022 third quarter financial and operational results. Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information. Other interested parties will be able to access the live audio webcast by registering on IMV website: https://ir.imv-inc.com/events-and-presentations. The webcast will be rec
Patient recruitment in the Phase 2B VITALIZE DLBCL trial of MVP-S plus Keytruda continues to track well, with first results expected in Q3 2022. Matthew J. Matasar, MD from Memorial Sloan Kettering Cancer Center, has joined VITALIZE as lead principal investigator of the study. First patient dosed in the Phase 2B AVALON platinum-resistant ovarian cancer trial of MVP-S plus intermittent low-dose cyclophosphamide, with early data expected in 1H 2023. IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its
IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, August 11, 2022, at 8:00 a.m. ET to discuss the company's 2022 second quarter financial and operational results. Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information. Other interested parties will be able to access the live audio webcast by registering on IMV website: https://ir.imv-inc.com/events-and-presentations
Positive clinical results in bladder cancer were presented at the AACR annual meeting, including 2 confirmed complete responses (CRs) and 3 partial responses (PRs) per RECIST v1.1; CRs and PRs were observed in patients previously treated with checkpoint inhibitors; Treatment with MVP-S/CPA and pembrolizumab was well-tolerated with mostly grade 1-2 injection site reactions, and no severe adverse events attributed to MVP-S; New data were presented about DPX-based therapies' mechanism of action. Results from preclinical and clinical studies demonstrate that Natural Killer (NK) cells are also involved in the anti-cancer efficacy of DPX-based therapy. Michael P. Bailey was appointed
IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, May 13, 2022, at 8:00 a.m. ET to discuss the company's 2022 first quarter financial and operational results. Financial analysts are invited to join the conference call by dialing 1-844-461-9932 (U.S. and Canada) or 1-636-812-6632 (international) and using the conference ID: 5396906 Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations
IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 17, 2022, at 8:00 a.m. ET to discuss the company's 2021 fourth quarter and fiscal year-end financial and operational results. Financial analysts are invited to join the conference call by dialing 1-844-461-9932 (U.S. and Canada) or 1-636-812-6632 (international) and using the conference ID: 5049587 Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentatio
IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating cancer therapies, based on its novel DPX platform, to treat solid and blood cancers while preserving patients' quality of life today announced that it will hold a conference call and webcast on Thursday, November 11, 2021 at 8:00 a.m. ET to discuss the company's third quarter 2021 financial and operational results. Financial analysts are invited to join the conference call by dialing (866) 211-3204 (U.S. and Canada) or (647) 689-6600 (international) and using the conference ID: 7079735 Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.co
Upgrades According to Colliers Securities, the prior rating for Centerspace (NYSE:CSR) was changed from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $1.07, compared to $0.98 from the year-ago quarter. The stock has a 52-week-high of $96.84 and a 52-week-low of $51.26. At the end of the last trading period, Centerspace closed at $56.87. According to Bernstein, the prior rating for Roper Technologies Inc (NYSE:ROP) was changed from Market Perform to Outperform. Roper Techs earned $3.90 in the first quarter, compared to $3.77 in the year-ago quarter. At the moment, the stock has a 52-week-high of $481.65 and a 52-week-low of $357.25. Roper Techs closed at $458.63 at the
HC Wainwright & Co. analyst Joseph Pantginis downgrades IMV (NASDAQ:IMV) from Buy to Neutral.
IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that the Nova Scotia Supreme Court (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries protection under the Companies' Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the "CCAA"). The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code.After a careful review of available opt
Gainers Clearmind Medicine Inc. (NASDAQ:CMND) gained 61.5% to $0.88 in pre-market trading after dropping around 3% on Tuesday. Clearmind engaged a contract research organization for its upcoming first-in-human study of MEAI compound while also filing an additional provisional patent application with partner SciSparc. SAI.TECH Global Corporation (NASDAQ:SAI) shares climbed 25.1% to $3.49 in pre-market trading after gaining 9% on Tuesday. SAI.TECH Global recently anounced appointments of Harry Sun to be Chief Technology Officer and Tao Wu to be Chief Operating Officer of SAI.TECH's new Product Line ULTIAAS. IN8bio, Inc. (NASDAQ:INAB) gained 20.4% to $2.30 in pre-market trading after drop
IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that on March 29, 2023, IMV Inc. (the "Company") received a letter from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") indicating that, based upon the closing bid price of the Company's common shares for the 30 consecutive business day period between February 14, 2023, through March 28, 2023, the Company did not meet the minimum bid price of US$1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listin
HC Wainwright & Co. analyst Joseph Pantginis reiterates IMV (NASDAQ:IMV) with a Buy, 1-for-10 reverse stock
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. • InfuSystems Holdings (AMEX:INFU) is projected to report quarterly earnings at $0.04 per share on revenue of $30.80 million. • Kandi Technologies Gr (NASDAQ:KNDI) is projected to report quarterly earnings at $0.02 per share on revenue of $49.30 million. • GDS Holdings (NASDAQ:GDS) is projected to report quarterly loss at $0.34 per share on revenue of $341.25 million. • Calumet Specialty (NASDAQ:CLMT) is likely to report quarterly earnings at $0.00 per share on revenue of $904.43 million. • Oatly Group (NASDAQ:OTLY) is likely to r
IMV (NASDAQ:IMV) is set to give its latest quarterly earnings report on Wednesday, 2023-03-15. Here's what investors need to know before the announcement. Analysts estimate that IMV will report an earnings per share (EPS) of $-1.20. IMV bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company beat EPS by $0.40, which was followed by a 4.09% drop in the share price the next day. Here's a
On Tuesday, 93 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Sirius XM Holdings (NASDAQ:SIRI) was the largest company by market cap to set a new 52-week low. The company with the smallest market cap to set a new 52-week low was Altamira Therapeutics (NASDAQ:CYTO). Cara Therapeutics (NASDAQ:CARA)'s stock fell the most, as it traded down 31.35% to reach a new 52-week low. Vintage Wine Estates (NASDAQ:VWE) saw the biggest bounce back on, as shares traded up 0.0% to rebound after it hit its new 52-week low. Here are all the stocks that set new 52-week lows on Tuesday: Sirius XM Holdings (NASDAQ:SIRI) shares were down 4.3% for the day, having made a